11 – 20 of 115
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tau-neurodegeneration mismatch reveals vulnerability and resilience to comorbidities in Alzheimer's continuum
(
- Contribution to journal › Article
-
Mark
Survey among experts on the future role of tau-PET in clinical practice and trials
(
- Contribution to journal › Article
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
How Do Modifiable Risk Factors Affect Alzheimer's Disease Pathology or Mitigate Its Effect on Clinical Symptom Expression?
(
- Contribution to journal › Scientific review
-
Mark
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology : a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein and tau : predictors of neurological outcome after cardiac arrest
(
- Contribution to journal › Article
-
Mark
Structural white matter properties and cognitive resilience to tau pathology
(
- Contribution to journal › Article
-
Mark
Overlaps and divergences between tauopathies and synucleinopathies : a duet of neurodegeneration
(
- Contribution to journal › Scientific review
-
Mark
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
(
- Contribution to journal › Article
-
Mark
Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
(
- Contribution to journal › Article